Latest news with #Biocytogen
National Post
17-06-2025
- Business
- National Post
Biocytogen Responds to Harbour BioMed's Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing
Article content BEIJING — In response to Harbour BioMed's recent press release regarding a procedural development in their ongoing legal claim, Biocytogen issues the following statement: Article content Biocytogen stands by its core values of independent innovation, respect for intellectual property, and a commitment to fair competition. The RenNano® platform is the result of independent, original R&D, based on Biocytogen's proprietary genome editing technologies. Its technical principles, design strategy, and IP scope are fundamentally different from the patents in dispute. Article content 120 vs. 9 – A Significant Technical Divide of RenNano® Platform Article content ; Article content Biocytogen Will Resolutely Take Legal Actions to Protect Its Rights Article content The RenNano® platform employs a large-fragment knock-in strategy that incorporates over 120 human V genes in situ, enabling a complete and functional human heavy chain antibody repertoire. In stark contrast, Harbour BioMed's HCAb platform introduces only 9 V genes through a small-fragment transgenic approach. This key difference reflects not only divergent technical strategies but also the depth, innovation, and translational potential of Biocytogen's antibody discovery platforms. Article content The decision referenced in Harbour BioMed's PR involves a procedural ruling on jurisdiction only and does not address the substance of the patent infringement case. Furthermore, the CNIPA's affirmation of patent validity is a routine administrative process that does not imply infringement. The underlying lawsuit has not yet entered the trial phase. Article content Biocytogen is currently evaluating all legal options and will resolutely defend its IP rights and scientific reputation. The RenNano® platform has been fully validated and is supported by a robust portfolio of domestic and international patents, clearly documenting its originality and independence. Article content We remain confident in: Article content The technical integrity and legal foundation of the RenNano® platform; The non-infringement of any third-party IP; Our continued leadership in antibody discovery and therapeutic innovation. Article content According to public records, the Chinese patent related to Harbour BioMed's HCAb platform is set to expire on July 22, 2025, further underscoring the short-sighted nature of any speculative claims. Regardless, Biocytogen will continue to uphold its rights, ensure business continuity, and deliver transformative technologies for global partners and patients. Article content Any misleading allegations or speculative narratives will not deter our team from advancing the RenMice® platform series with world-class innovation and delivering on our mission to accelerate therapeutic discovery. Article content Biocytogen's RenNano® Platform and Harbour BioMed's HCAb Platform Article content Biocytogen RenNano® Platform: Uses large-fragment knock-in technology to replace mouse genes with over 120 human V genes in situ, resulting in a full and functional human heavy chain variable region genomic repertoire. Harbour BioMed HCAb Platform: Introduces only 9 V genes using small-fragment transgenic approaches. Article content About Biocytogen Article content Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit Article content Article content Article content Contacts Article content Biocytogen Contacts Article content Article content Antibody platform and assets: Article content BD-Licensing@ Article content Article content Preclinical models and services: Article content Article content
Business Wire
17-06-2025
- Business
- Business Wire
Biocytogen Responds to Harbour BioMed's Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing
BEIJING--(BUSINESS WIRE)--In response to Harbour BioMed's recent press release regarding a procedural development in their ongoing legal claim, Biocytogen issues the following statement: Biocytogen stands by its core values of independent innovation, respect for intellectual property, and a commitment to fair competition. The RenNano® platform is the result of independent, original R&D, based on Biocytogen's proprietary genome editing technologies. Its technical principles, design strategy, and IP scope are fundamentally different from the patents in dispute. 120 vs. 9 – A Significant Technical Divide of RenNano® Platform; Biocytogen Will Resolutely Take Legal Actions to Protect Its Rights The RenNano® platform employs a large-fragment knock-in strategy that incorporates over 120 human V genes in situ, enabling a complete and functional human heavy chain antibody repertoire. In stark contrast, Harbour BioMed's HCAb platform introduces only 9 V genes through a small-fragment transgenic approach. This key difference reflects not only divergent technical strategies but also the depth, innovation, and translational potential of Biocytogen's antibody discovery platforms. The decision referenced in Harbour BioMed's PR involves a procedural ruling on jurisdiction only and does not address the substance of the patent infringement case. Furthermore, the CNIPA's affirmation of patent validity is a routine administrative process that does not imply infringement. The underlying lawsuit has not yet entered the trial phase. Biocytogen is currently evaluating all legal options and will resolutely defend its IP rights and scientific reputation. The RenNano® platform has been fully validated and is supported by a robust portfolio of domestic and international patents, clearly documenting its originality and independence. We remain confident in: The technical integrity and legal foundation of the RenNano® platform; The non-infringement of any third-party IP; Our continued leadership in antibody discovery and therapeutic innovation. According to public records, the Chinese patent related to Harbour BioMed's HCAb platform is set to expire on July 22, 2025, further underscoring the short-sighted nature of any speculative claims. Regardless, Biocytogen will continue to uphold its rights, ensure business continuity, and deliver transformative technologies for global partners and patients. Any misleading allegations or speculative narratives will not deter our team from advancing the RenMice® platform series with world-class innovation and delivering on our mission to accelerate therapeutic discovery. Key Technical Differences Between Biocytogen's RenNano® Platform and Harbour BioMed's HCAb Platform Biocytogen RenNano® Platform: Uses large-fragment knock-in technology to replace mouse genes with over 120 human V genes in situ, resulting in a full and functional human heavy chain variable region genomic repertoire. Harbour BioMed HCAb Platform: Introduces only 9 V genes using small-fragment transgenic approaches. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit
Malaysian Reserve
16-06-2025
- Business
- Malaysian Reserve
China National Intellectual Property Administration Affirms Validity of Harbour BioMed's Patent; Infringement Lawsuit Moves Forward
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SHANGHAI, June 16, 2025 /PRNewswire/ — Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and oncology, today announced key developments in its intellectual property (IP) protection efforts. Following an invalidation request filed by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ('Biocytogen') against Harbour BioMed's patent entitled 'Binding Molecule' (Patent Application No. CN201210057668.0, the 'HCAb Patent'), the China National Intellectual Property Administration ('CNIPA') issued a final decision on June 5, 2025, upholding the patent under Articles 22.3, 26.3, 26.4, and 33 of the Patent Law of the People's Republic of China. The HCAb patent covers a method for producing fully human heavy chain-only antibodies (HCAbs) utilizing transgenic animals. On September 27, 2024, Harbour BioMed filed a patent infringement lawsuit with the Shanghai Intellectual Property Court against Biocytogen, alleging that its RenNano platform infringes Harbour BioMed's HCAb Patent. Biocytogen subsequently challenged the court's jurisdiction, first through an objection submitted to the Shanghai Intellectual Property Court on November 8, 2024, and later through an appeal to the Supreme People's Court of the People's Republic of China on March 14, 2025. On May 27, 2025, the Supreme People's Court of the People's Republic of China issued a final ruling, dismissing the appeal and affirming the jurisdiction of the Shanghai Intellectual Property Court over the infringement lawsuit. This case has now advanced to the next stage of trial. Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented: 'CNIPA's decision affirms the rightful protections of the pioneering innovation and core value of Harbour BioMed's intellectual property. We have established a global patent portfolio across key markets, providing robust protection for R&D investments and proprietary innovations enabled by our Harbour Mice® platform and associated technologies. Moving forward, we will continue to leverage our patented HCAb technology to accelerate the development of transformative therapies in collaboration with global partners, ultimately bringing meaningful benefits to patients worldwide.' About Harbour BioMed Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions. Harbour BioMed's proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICATM) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice®, HBICE®, and HBICATM with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit
Yahoo
16-06-2025
- Business
- Yahoo
China National Intellectual Property Administration Affirms Validity of Harbour BioMed's Patent; Infringement Lawsuit Moves Forward
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SHANGHAI, June 16, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and oncology, today announced key developments in its intellectual property (IP) protection efforts. Following an invalidation request filed by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") against Harbour BioMed's patent entitled "Binding Molecule" (Patent Application No. CN201210057668.0, the "HCAb Patent"), the China National Intellectual Property Administration ("CNIPA") issued a final decision on June 5, 2025, upholding the patent under Articles 22.3, 26.3, 26.4, and 33 of the Patent Law of the People's Republic of China. The HCAb patent covers a method for producing fully human heavy chain-only antibodies (HCAbs) utilizing transgenic animals. On September 27, 2024, Harbour BioMed filed a patent infringement lawsuit with the Shanghai Intellectual Property Court against Biocytogen, alleging that its RenNano platform infringes Harbour BioMed's HCAb Patent. Biocytogen subsequently challenged the court's jurisdiction, first through an objection submitted to the Shanghai Intellectual Property Court on November 8, 2024, and later through an appeal to the Supreme People's Court of the People's Republic of China on March 14, 2025. On May 27, 2025, the Supreme People's Court of the People's Republic of China issued a final ruling, dismissing the appeal and affirming the jurisdiction of the Shanghai Intellectual Property Court over the infringement lawsuit. This case has now advanced to the next stage of trial. Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented: "CNIPA's decision affirms the rightful protections of the pioneering innovation and core value of Harbour BioMed's intellectual property. We have established a global patent portfolio across key markets, providing robust protection for R&D investments and proprietary innovations enabled by our Harbour Mice® platform and associated technologies. Moving forward, we will continue to leverage our patented HCAb technology to accelerate the development of transformative therapies in collaboration with global partners, ultimately bringing meaningful benefits to patients worldwide." About Harbour BioMed Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions. Harbour BioMed's proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICATM) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice®, HBICE®, and HBICATM with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit View original content to download multimedia: SOURCE Harbour BioMed
National Post
05-06-2025
- Business
- National Post
Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform
Article content BEIJING — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) today announced that the key technology of its independently developed RenMab™ fully human antibody mouse platform has been granted an invention patent by the Japan Patent Office (JPO). This milestone marks a significant step in strengthening the global intellectual property portfolio of the RenMice ® fully human antibody platform family. It underscores the continued advancement of Biocytogen's comprehensive global patent strategy and highlights the innovation and international recognition of the company's proprietary technologies. Article content RenMab™ mice are a core member of Biocytogen's independently developed RenMice ® fully human antibody discovery platform family. Using Biocytogen's proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCE ®) technology, the complete repertoire of murine immunoglobulin heavy chain and light chain variable region genes was precisely replaced in situ with their human counterparts. As a result, RenMab mice have the full repertoire of human antibody heavy chain VDJ and light chain VJ genes. It retains the ability to mount robust immune responses against diverse antigens, comparable to wild-type mice, and can generate fully human antibodies with native-like diversity, significantly improving the efficiency and success rate of discovering high-potential therapeutic candidates. Importantly, antibodies derived from RenMab mice require no additional humanization, effectively minimizing immunogenicity risks and streamlining the antibody drug development process. Article content With distinct advantages in discovering fully human antibodies and TCRs with low immunogenicity, high diversity, favorable affinity, and excellent physicochemical properties, Biocytogen's RenMice platform series (RenMab™/RenLite ® /RenNano ® /RenTCR-mimic™/RenTCR™) has gained widespread recognition in the global biotech and biopharmaceutical industry. Licensing agreements have been established with 20+ companies, including Merck KGaA, Darmstadt, Germany, Janssen/ Johnson & Johnson, and BeiGene. Leveraging the RenMice platform, the RenBiologics™ program has generated over 1,000,000 fully human antibody sequences and numerous high-potential preclinical candidates against more than 1,000 therapeutic targets. As of December 31, 2024, approximately 200 agreements encompassing therapeutic antibody co-development, out-licensing, and asset transfers have been executed, highlighting the RenMice platform's strong global competitiveness and significant commercial value. Article content With its sustained independent research and cutting-edge technological innovation capabilities, Biocytogen has been actively advancing its global patent portfolio and key technology protections for the RenMice ® platform. To date, the RenMice platform has secured patent grants in nearly 10 countries, including the U.S., China, and Japan, while nearly 40 patent applications are under examination across 15 countries and regions. With the steady progress of the global patent strategy, additional patent grants are anticipated in the near term. This strong intellectual property protection framework will continue to deliver reliable assurance to Biocytogen's partners worldwide. Article content About Biocytogen Article content Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice ® (RenMab™/ RenLite ® / RenNano ® / RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice ® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit Article content Article content Article content Contacts Article content Biocytogen Contacts Article content Article content Antibody assets and platforms: Article content Article content Article content
